Topical treatment in vitiligo and the potential uses of new drug delivery systems

被引:31
|
作者
Garg, Bhawna Jain [1 ]
Saraswat, Abir [2 ]
Bhatia, Amit [1 ]
Katare, Om Prakash [1 ]
机构
[1] Panjab Univ, Ctr Adv Studies, Univ Inst Pharmaceut Sci UGC, Chandigarh 160014, India
[2] Skin Clin, Lucknow, Uttar Pradesh, India
关键词
Novel drug delivery; phospholipid-based carriers; topical therapies; vitiligo; SOLID LIPID NANOPARTICLES; IN-VITRO; DOUBLE-BLIND; CARRIERS; SKIN; THERAPY; VIVO; REPIGMENTATION; PIMECROLIMUS; FORMULATION;
D O I
10.4103/0378-6323.62961
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Vitiligo is a psychologically devastating condition. Topical therapy is employed as first-line treatment in localized vitiligo. Currently, several topical agents are available in many forms viz. methoxsalen (solution and cream), trioxsalen (solution), corticosteroids (gel, cream, ointment and solution) and calcineurin inhibitors (ointment and cream). Although topical therapy has an important position in vitiligo treatment, side-effects or poor efficacy affect their utility and patient compliance. Novel drug delivery strategies can play a pivotal role in improving the topical delivery of various drugs by enhancing their epidermal localization with a concomitant reduction in their side-effects and improving their effectiveness. The current review emphasizes the potential of various phospholipid based carriers viz. liposomes, transferosomes, ethosomes, lipid emulsions, solid lipid nanoparticles and organogels in optimizing and enhancing the topical delivery of anti-vitiligo agents, whilst reducing the side effects of drugs commonly used in its topical treatment.
引用
收藏
页码:231 / 237
页数:7
相关论文
共 50 条
  • [1] Pharmacokinetics of topical ocular drug delivery: Potential uses for the treatment of diseases of the posterior segment and beyond
    Koevary, SB
    [J]. CURRENT DRUG METABOLISM, 2003, 4 (03) : 213 - 222
  • [2] Rosacea Topical Treatment and Care: From Traditional to New Drug Delivery Systems
    Paiva-Santos, Ana Claïudia
    Goncalves, Tatiana
    Peixoto, Diana
    Pires, Patriïcia C.
    Velsankar, K.
    Jha, Niraj Kumar
    Chavda, Vivek P. P.
    Mohammad, Imran Shair
    Cefali, Letiïcia Caramori
    Mazzola, Priscila Gava
    Mascarenhas-Melo, Filipa
    Veiga, Francisco
    [J]. MOLECULAR PHARMACEUTICS, 2023, 20 (08) : 3804 - 3828
  • [3] Drug delivery systems for the topical treatment of cutaneous leishmaniasis
    Carneiro, Guilherme
    Aguiar, Marta Gontijo
    Fernandes, Ana Paula
    Miranda Ferreira, Lucas Antonio
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2012, 9 (09) : 1083 - 1097
  • [4] Potential of novel drug delivery systems in the management of topical candidiasis
    Mathur, Mahima
    Devi, V. Kusum
    [J]. JOURNAL OF DRUG TARGETING, 2017, 25 (08) : 685 - 703
  • [5] Topical ruxolitinib: A new treatment for vitiligo
    Tavoletti, G.
    Avallone, G.
    Conforti, C.
    Roccuzzo, G.
    Maronese, C. A.
    Mattioli, M. A.
    Quaglino, P.
    Zalaudek, I.
    Marzano, A. V.
    Ribero, S.
    Alberti-Violetti, S.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (11) : 2222 - 2230
  • [6] Novel drug delivery systems: Potential in improving topical delivery of antiacne agents
    Date, AA
    Naik, B
    Nagarsenker, MS
    [J]. SKIN PHARMACOLOGY AND PHYSIOLOGY, 2006, 19 (01) : 2 - 16
  • [7] Nanoparticles for topical drug delivery: Potential for skin cancer treatment
    Krishnan, Vinu
    Mitragotri, Samir
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2020, 153 : 87 - 108
  • [8] PHYSICOCHEMICAL AND BIOLOGIC PROPERTIES OF INTERFERONS AND THEIR POTENTIAL USES IN DRUG DELIVERY SYSTEMS
    BOCCI, V
    [J]. CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 1992, 9 (02): : 91 - 133
  • [9] A new preparation of khellin in the topical treatment of vitiligo
    Orecchia, G
    Giordano, F
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 106 (04) : 834 - 834
  • [10] In situ gelling drug delivery systems for topical drug delivery
    Kolawole, Oluwadamilola M.
    Cook, Michael T.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2023, 184 : 36 - 49